Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging trial of farglitazar in chronic hepatitis C with hepatic fibrosis after antiviral failure
2005-000995-41Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of farglitazar in hepatitis C virus infection and hepatic fibrosis (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in liver biopsy immunohistochemical markers of hepatic stellate cell activation and collagen synthesis. Started Dec 2005; status: completed.
02
Drugs
farglitazar
03
Conditions
hepatitis C virus infectionhepatic fibrosis
Beyond the preview
Go deeper on 2005-000995-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000995-41.